ArticleReproductive medicine and biology
Post Hoc Analysis of a Previous Study of Estetrol 15 mg/Drospirenone 3 mg Combination for Dysmenorrhea and Uterine Bleeding in Adenomyosis Patients.
Article in Reproductive medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Estetrol/drospirenone for combined oral contraception: a systematic review of efficacy, cycle control, and safety.Frontiers in endocrinology · 2026Pooled it
- Post Hoc Analysis of a Previous Study of Estetrol 15 mg/Drospirenone 3 mg Combination for Dysmenorrhea and Uterine Bleeding in Adenomyosis Patients.Reproductive medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To clarify the efficacy and safety of the estetrol 15 mg/drospirenone 3 mg combination among Japanese women with adenomyosis by post hoc analyses of a previous randomized clinical study. Methods: Post hoc analyses were performed using data from a 16-week, multi-center, randomized, double-blinded, placebo-controlled, parallel-group study, followed by a 36-week, open-label extension study involving 162 Japanese women with dysmenorrhea. Participants received cyclic estetrol/drospirenone or placebo. The primary endpoint was the absolute change in total dysmenorrhea score from baseline to the end of the 16-week double-blinded period. Results: Among participants with adenomyosis, estetrol/drospirenone reduced the change from baseline of the total dysmenorrhea score at Week 16 by 2.5. The between-treatment difference was estimated as -1.8 (two-sided 95% confidence interval: -2.5 to -1.0), showing a significant difference from placebo ( Conclusions: Estetrol/drospirenone ameliorates adenomyosis-associated symptoms, offering safer treatment with potentially reduced thromboembolic risk. Trial Registration: jRCT registration number: jRCT2011210023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.